Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction

J Cardiovasc Med

20 August Aug 2020 one month ago
  • Mapelli M, Salvioni E, de Martino F, Mattavelli I, Bonomi A, Gugliandolo P, Vignati C, Magini A, Paolillo S, Agostoni P

Practice guidelines recommend sacubitril/valsartan for heart failure with reduced ejection fraction. The aim of our study was to describe the use of sacubitril/valsartan in real-world clinical practice to help identify patients best able to tolerate titration to higher doses.

Reference

Mapelli M, Salvioni E, de Martino F, Mattavelli I, Bonomi A, Sassi V, Gugliandolo P, Vignati C, Magini A, Rovai S, Paolillo S, Agostoni P. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction. J Cardiovasc Med (Hagerstown) 2020 Jul 17. doi: 10.2459/JCM.0000000000001018.

Go to PubMed